AKTing on XPO1 inhibition in AML

被引：0

作者：

Goellner, Stefanie ^{[1
]}

Mueller-Tidow, Carsten ^{[1
,2
,3
,4
]}

机构：

[1] Univ Hosp Heidelberg, Dept Med Hematol Oncol & Rheumatol 5, Heidelberg, Germany

[2] European Mol Biol Lab, Mol Med Partnership Unit, Heidelberg, Germany

[3] Heidelberg Univ, Heidelberg, Germany

[4] Natl Ctr Tumor Dis, Heidelberg, Germany

来源：

NATURE CANCER | 2022年 / 3卷 / 07期

关键词：

NUCLEAR EXPORT; C/EBP-BETA; EXPRESSION; CRM1;

D O I：

10.1038/s43018-022-00395-w

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Inhibition of XPO1-mediated nuclear export by selinexor represents a promising therapeutic strategy in acute myeloid leukemia. Because XPO1 is not specific for tumor-suppressive proteins, selinexor may also activate pro-oncogenic processes. A study now shows that inhibition of selinexor-induced, purinergic receptor-mediated AKT activation potentiates its anti-leukemic activity.

引用

页码：787 / 789

页数：3

共 50 条

[41] Hitting a moving target: inhibition of the nuclear export receptor XPO1/CRM1 as a therapeutic approach in cancer
Sendino, Maria
Josu Omaetxebarria, Miren
Antonio Rodriguez, Jose
CANCER DRUG RESISTANCE, 2018, 1 (03) : 139 - 163
[42] XPO1 is selinexor prime target: validation by mutating cysteine 528 on both XPO1 alleles using CRISPR/Cas9 genome editing
Neggers, Jasper E.
Vercruysse, Thomas
Jacquemyn, Maarten
Vanstreels, Els
Baloglu, Erkan
Shacham, Sharon
Crochiere, Marsha
Senapedis, William
Landesman, Yosef
Daelemans, Dirk
CANCER RESEARCH, 2015, 75
[43] Azacitidine Is Synergistically Lethal with XPO1 Inhibitor Selinexor in Acute Myeloid Leukemia by Targeting XPO1/eIF4E/c-MYC Signaling
Long, Huideng
Hou, Yue
Li, Jun
Song, Chunhua
Ge, Zheng
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (07)
[44] XPO1 is a new target of homoharringtonine (HHT): Making NPMc plus AML cells much more sensitive to HHT treatment
Xue, Jingjing
Chu, Peng
Gao, Wenjuan
Wang, Furong
Gao, Yuan
Liu, Shuqing
Kang, Zhijie
Yan, Jinsong
Wang, Haina
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2023, 675 : 155 - 161
[45] Expression of exportin 1 (XPO1/CRM1) in pancreatic adenocarcinoma
Saulino, David M.
Younes, Pamela S.
Biley, Jennifer M.
Younes, Mamoun
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
[46] XPO1 inhibition synergizes with PARP1 inhibition in small cell lung cancer by targeting nuclear transport of FOXO3a
Wang, Jingya
Sun, Tao
Meng, Zhaoting
Wang, Liuchun
Li, Mengjie
Chen, Jinliang
Qin, Tingting
Yu, Jiangyong
Zhang, Miao
Bie, Zhixin
Dong, Zhiqiang
Jiang, Xiangli
Li Lin
Zhang, Cuicui
Liu, Zhujun
Jiang, Richeng
Yang, Guang
Li, Lin
Zhang, Yan
Huang, Dingzhi
CANCER LETTERS, 2021, 503 : 197 - 212
[47] Inhibiting the nuclear exporter XPO1 and the antiapoptotic factor BCL2 is synergistic in XPO1 and SF3B1 mutant hematologic malignancies.
Totiger, Tulasigeri M.
Chaudhry, Sana
Afaghani, Jumana
Taylor, Justin
CANCER RESEARCH, 2021, 81 (13)
[48] XPO1 INHIBITION USING SELINEXOR RESTORES TOPOISOMERASE IIA (TOPO IIA) LOCALIZATION TO THE NUCLEUS AND SENSITIZE PIMARY REFRACTORY AND RELAPSED ACUTE MYELOID LEUKEMIA (AML) BLASTS TO CHEMOTHERAPY
Yu, X.
Ranganathan, P.
Bhatnagar, B.
Hofstetter, J.
Shacham, S.
Kauffman, M.
Blum, W.
Garzon, R.
HAEMATOLOGICA, 2014, 99 : 292 - 293
[49] XPO1 regulates erythroid differentiation and is a new target for the treatment of β-thalassemia
Guillem, Flavia
Dussiot, Michael
Colin, Elia
Suriyun, Thunwarat
Ariet, Jean Benoit
Goudin, Nicolas
Marcion, Guillaume
Seigneuric, Renaud
Causse, Sebastien
Gonin, Patrick
Gastou, Marc
Deloger, Marc
Rossignol, Julien
Lamarque, Mathilde
Choucair, Zakia Belaid
Gautier, Emilie Fleur
Ducamp, Sarah
Vandekerckhove, Julie
Moura, Ivan C.
Maciel, Thiago Trovati
Garrido, Carmen
An, Xiuli
Mayeux, Patrick
Mohandas, Narla
Courtois, Genevieve
Hermine, Olivier
HAEMATOLOGICA, 2020, 105 (09) : 2240 - 2249
[50] Targeting XPO1 overexpression with selinexor disrupts the survivin pathway in neuroblastoma
Castellanos, Raquel
Galinski, Basia
Tauber, David
Landesman, Yosef
Attiyeh, Edward
Weiser, Daniel
CANCER RESEARCH, 2016, 76

← 1 2 3 4 5 →